

# Acute respiratory distress syndrome (ARDS) - Pipeline Insight, 2021

<https://marketpublishers.com/r/A7D445B59BEEN.html>

Date: May 2021

Pages: 150

Price: US\$ 2,500.00 (Single User License)

ID: A7D445B59BEEN

## Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "Acute respiratory distress syndrome (ARDS) - Pipeline Insight, 2021," report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Acute respiratory distress syndrome (ARDS) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Acute respiratory distress syndrome (ARDS) Understanding

#### Acute respiratory distress syndrome (ARDS): Overview

Acute respiratory distress syndrome (ARDS) is a life-threatening acute lung injury commonly resulting from sepsis, trauma, and severe pulmonary infections that allows fluid to leak into the lungs. The signs and symptoms of ARDS vary in intensity, depending on its cause and severity, including severe shortness of breath, unusual rapid breathing, low blood pressure, confusion and extreme tiredness. Along with medical history and physical examination, tests that help in diagnosis of ARDS are imaging tests, blood tests, and/or echocardiogram. Treatment options for ARDS include mechanical ventilation, fluid management, pharmacological treatment, extracorporeal

lung support strategies, and other supportive measures. Gene therapy and stem cell therapy are under clinical investigation for the treatment of ARDS.

'Acute respiratory distress syndrome (ARDS) - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute respiratory distress syndrome (ARDS) pipeline landscape is provided which includes the disease overview and Acute respiratory distress syndrome (ARDS) treatment guidelines. The assessment part of the report embraces, in depth Acute respiratory distress syndrome (ARDS) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute respiratory distress syndrome (ARDS) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Acute respiratory distress syndrome (ARDS) R&D. The therapies under development are focused on novel approaches to treat/improve Acute respiratory distress syndrome (ARDS).

## Acute respiratory distress syndrome (ARDS) Emerging Drugs Chapters

This segment of the Acute respiratory distress syndrome (ARDS) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Acute respiratory distress syndrome (ARDS) Emerging Drugs

### BIO-11006: BioMarck Pharmaceuticals

BIO-11006 is a novel peptide that inhibits the pro-inflammatory effects of overactive MARCKS protein. It is a ten-amino acid peptide that inhibits the phosphorylation of the

MARCKS protein (myristoylated alanine rich protein kinase C substrate), which is a substrate for protein kinase C. BIO-11006 is in Phase II clinical studies for the treatment of Adult respiratory distress syndrome, chronic obstructive pulmonary disease, and Non-small cell lung cancer.

### MultiStem: Athersys

MultiStem is an 'off-the-shelf' stem cell product candidate, manufactured from Multipotent Adult Progenitor Cells. These cells are distinct from mesenchymal stem cells (MSCs) and other cell types. The drug is in Phase III clinical studies for the treatment of ischemic stroke and acute respiratory distress syndrome (ARDS). The therapy has the equivalent of Fast Track status in Japan. In September 2020, Athersys announced that MultiStem cell therapy was granted Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for the acute respiratory distress syndrome (ARDS) program.

Further product details are provided in the report..

### Acute respiratory distress syndrome (ARDS): Therapeutic Assessment

This segment of the report provides insights about the different Acute respiratory distress syndrome (ARDS) drugs segregated based on following parameters that define the scope of the report, such as:

#### Major Players in Acute respiratory distress syndrome (ARDS)

There are approx. 60+ key companies which are developing the therapies for Acute respiratory distress syndrome (ARDS). The companies which have their Acute respiratory distress syndrome (ARDS) drug candidates in the most advanced stage, i.e. Phase III include, Athersys.

#### Phases

DelveInsight's report covers around 60+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Acute respiratory distress syndrome (ARDS) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute respiratory distress syndrome (ARDS): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Acute respiratory distress syndrome (ARDS) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute respiratory distress syndrome (ARDS) drugs.

Acute respiratory distress syndrome (ARDS) Report Insights

Acute respiratory distress syndrome (ARDS) Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Acute respiratory distress syndrome (ARDS) Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## Key Questions

### Current Treatment Scenario and Emerging Therapies:

How many companies are developing Acute respiratory distress syndrome (ARDS) drugs?

How many Acute respiratory distress syndrome (ARDS) drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute respiratory distress syndrome (ARDS)?

What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acute respiratory distress syndrome (ARDS) therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Acute respiratory distress syndrome (ARDS) and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

Faron Pharmaceuticals

BioMarck Pharmaceuticals

Athersys

Apeiron Biologics

Cynata Therapeutics

Orbsen Therapeutics

GEn1E Lifesciences

Exvastat

Longeveron

CohBar

ZyVersa Therapeutics

Abbreos

Aviceda Therapeutics

ImStem Biotechnology

Bayer

AVM Biotechnology

Cartesian Therapeutics

Sage Therapeutics

Roivant Sciences

ZyVersa Therapeutics

Aerpio Pharmaceuticals

Apeiron Biologics

## Key Products

Traumakine

BIO-11006

HLCM 051

APN-01

CYP 001

Orbcel-C

GEn1E-1124

Imatinib

Lomecel-B

CB5064 analogs

IC 100

ABB-201

IMS 001

AVD-1010

BAY 1097761

AVM0703

Descartes-30

Brexanolone

Gimsilumab



IC 100

Razuprotafib

APN401

## Contents

Introduction

Executive Summary

Acute respiratory distress syndrome (ARDS): Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Acute respiratory distress syndrome (ARDS) – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Acute respiratory distress syndrome (ARDS) companies' collaborations, Licensing, Acquisition -Deal Value Trends

Acute respiratory distress syndrome (ARDS) Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Traumakine: Faron Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Mid Stage Products (Phase II)

Comparative Analysis

BIO-11006: BioMarck Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Early Stage Products (Phase I)

Comparative Analysis

GEN1E-1124: GEN1E Lifesciences

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Preclinical/Discovery Stage Products

Comparative Analysis

IC 100: ZyVersa Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Inactive Products

Comparative Analysis

Acute respiratory distress syndrome (ARDS) Key Companies

Acute respiratory distress syndrome (ARDS) Key Products

Acute respiratory distress syndrome (ARDS)- Unmet Needs

Acute respiratory distress syndrome (ARDS)- Market Drivers and Barriers

Acute respiratory distress syndrome (ARDS)- Future Perspectives and Conclusion

Acute respiratory distress syndrome (ARDS) Analyst Views

Acute respiratory distress syndrome (ARDS) Key Companies

Appendix

## List Of Tables

### LIST OF TABLES

Table 1 Total Products for Acute respiratory distress syndrome (ARDS)

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

Figure 1 Total Products for Acute respiratory distress syndrome (ARDS)

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

## I would like to order

Product name: Acute respiratory distress syndrome (ARDS) - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/A7D445B59BEEN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A7D445B59BEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970